MedScreen Programs Pharmacist Check for Quality Use of Medicines Cardiovascular Disease MedScreen Rosuvastatin Schedule Period active: 01 July 2014 – 30 September 2014 MedScreen Rosuvastatin 2014 Aim This program aims to enhance the quality use of Rosuvastatin in patients already taking the therapy. Qualification Criteria • • • The patient must have previous history of Rosuvastatin (e.g. not New to Therapy) o This check is completed by the GuildCare software. It will attempt to calculate a MedsIndex score using dispense history or repeat information. If no score can be calculated, the patient will be deemed “new to therapy” and will not be invited into the program. The GuildCare software will identify patients based on all the PBS item codes for all strengths of Rosuvastatin. All patients taking Rosuvastatin under these criteria regardless of age. Clinical The Clinical services follow the MedScreen Protocol ‘clinical basis’. Here is the rationale of QUM questions and considerations: Question Rationale/Considerations What do you know about • Assess the patient’s knowledge of their medicine and condition Rosuvastatin and the reason • If required, address knowledge gaps you’ve had it prescribed? • This helps to enhance the patient’s sense of importance to the medicine for their health How often do you take • Assess the patient’s perceived level of compliance and use the displayed MedsIndex Rosuvastatin and what routine do score to quickly discuss their probable level of compliance. you follow? • With the patient, establish an achievable daily routine to enhance the patient’s compliance What do you feel have been the • Assess whether the patient has experienced the intended benefits and/or suffered benefits and drawbacks of taking drawbacks from taking the medicine Rosuvastatin on your health? (e.g. • Discussing health benefits helps to enhance the patient’s sense of importance of Adverse Effects, Lifestyle benefits) Rosuvastatin for their long term health • Identifying drawbacks can help to work towards more appropriate use of the medicine and better compliance This approach follows the National Strategy for QUM as discussed in the MedScreen Programs Protocol. Comments Research shows that compliance to ‘statin’ medications is poor and gets worse over time. After one year 47.5% of patients have 1 a MedsIndex < 80 (e.g. less than 9 scripts/year) and this reduces to only 25% of patients after 5 years. The reasons for this poor compliance include knowledge of the medicine, side effects and not experiencing any perceived benefits. As a relatively symptomless condition, hypercholesterolaemia can be difficult to treat due to poor patient compliance. The impact pharmacists can make is substantial with research suggesting that quality use of Rosuvastatin can be improved with communication, education and follow-up. Pharmacists are strongly encouraged to use MedScreen as an avenue to initiate discussion and provide further assistance to patients. Useful Resources Title Rosuvastatin CMI & PI Australian Medicines Handbook Therapeutic Guidelines Author/Source Manufacturer Cardiovascular Drugs Cardiovascular version 5 2008 Link http://www.medicines.org.au Stroke Foundation Website 1. Factors Related to Adherence to Statin Therapy McGinnis B et al. Ann Pharmacotherapy. 2007;41(11):1805-11. http://www.strokefoundation.com.au http://www.medscape.com/viewarticle/565773 GuildCare MedScreen Programs Rosuvastatin Schedule © GuildLink Pty Ltd 2014 Version 1.0
© Copyright 2024 ExpyDoc
